Decoding Biology

Simulating disease network dynamics to reduce translational risk.

Partner with Us

{

What we propose

}

Bridging the Translational Gap

{

The challenge

}

Why Promising Drugs Still Fail

A lot of promising drugs fail in clinical trials, leaving patients waiting for treatments they desperately need.

High Failure Rates
The overall success rate of a drug passing through all clinical trials is 8.4%. Depending on the therapeutic area the range is from 3.9% for infectious disease to 34.1% for blood borne diseases.
Lack of Efficacy
Phase 2 trials that test if the drug is effective, have the lowest probability of success, ranging from 27.4% for respiratory diseases to 52.7% for ophthalmology.
Unclear MoA
Lack of Efficacy results from poorly understood disease biology. How does the target to which the drug binds to modulate the disease (Mechanism of Action - MoA)?

"Target validation without clinical context and insufficient mechanistic understanding are the major reasons for high clinical attrition"

{

How we do it

}

We Tackle the Root Cause.

Causal simulation. Biomarker trajectory modeling. Mechanism-aware target evaluation.

Built for you, To decode biology.

From static snapshots to dynamic insights
From prediction patterns to prognostic simulation
Simulate relative system behavior under different target perturbations to compare mechanistic hypotheses

EndoGenics™
Beta

A mechanism-based modelling and simulation platform. Developed from first principles.

EndoClinics ™
Coming soon

A customized user interface for insights of potential clinical outcomes on the basis of in-house and public research data on COVID.

{

Our advancements

}

News and Insights

A New Simulation Engine

Biology is becoming more complex with the rise of omics data and interconnected systems. At BioFi, our Endogenics Simulation Engine (ESE) models and simulates these processes to unlock insights and accelerate drug discovery.

July 2025

European Commission funds research to tackle long-term COVID-19 health impact

The POINT project seeks to develop innovative strategies for the prevention and management of non-communicable diseases that arise as complications during the post-acute phase of COVID-19.

June 2024